Genetically engineered Lactococcus lactis strain constitutively expresses GABA-producing genes and produces high levels of GABA
Letters in Applied Microbiology · 2024
DOI: 10.1093/lambio/ovae051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied Microbiology, 2024. Verfasst von Marcos P Monteiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, RRC 3070, Atlanta, GA 30322, United States. Hauptthemen laut MEDLINE: Lactococcus lactis, gamma-Aminobutyric Acid, Promoter Regions, Genetic, Glutamate Decarboxylase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
γ-Aminobutyric acid (GABA) is an inhibitory neurotransmitter of the central nervous system that impacts physical and mental health. Low GABA levels have been documented in several diseases, including multiple sclerosis and depression, and studies suggest that GABA could improve disease outcomes in those conditions. Probiotic bacteria naturally produce GABA and have been engineered to enhance its synthesis. Strains engineered thus far use inducible expression systems that require the addition of exogenous molecules, which complicates their development as therapeutics. This study aimed to overcome this challenge by engineering Lactococcus lactis with a constitutive GABA synthesis gene cassette. GABA synthesizing and transport genes (gadB and gadC) were cloned onto plasmids downstream of constitutive L. lactis promoters [P2, P5, shortened P8 (P8s)] of different strengths and transformed into L. lactis. Fold increase in gadCB expression conferred by these promoters (P2, P5, and P8s) was 322, 422, and 627, respectively, compared to the unmodified strain (P = 0.0325, P8s). GABA synthesis in the highest gadCB expressing strain, L. lactis-P8s-glutamic acid decarboxylase (GAD), was dependent on media supplementation with glutamic acid and significantly higher than the unmodified strain (P < 0.0001, 125 mM, 200 mM glutamic acid). Lactococcus lactis-P8s-GAD is poised for therapeutic testing in animal models of low-GABA-associated disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, RRC 3070, Atlanta, GA 30322, United States.
- Department of Biology, Eastern Washington University, 1175 Washington St. Science 226, Cheney, WA 99004, United States.
- Department of Pharmacotherapy, Washington State University, 205 East Spokane Falls Boulevard, Spokane, WA 99202, United States.
- Department of Biological Sciences, Boise State University, 1910 University Drive, Boise, ID 83725, United States.
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- NIH HHS
- NCRR NIH HHS
- National Science Foundation
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Monteiro, M. P., Kohl, H. M., Roullet, J. B., Gibson, K. M., Ochoa-Repáraz, J., & Castillo, A. R. (2024). Genetically engineered Lactococcus lactis strain constitutively expresses GABA-producing genes and produces high levels of GABA. Letters in Applied Microbiology. https://doi.org/10.1093/lambio/ovae051
Vancouver
Monteiro MP, Kohl HM, Roullet JB, Gibson KM, Ochoa-Repáraz J, Castillo AR. Genetically engineered Lactococcus lactis strain constitutively expresses GABA-producing genes and produces high levels of GABA. Letters in Applied Microbiology. 2024. doi:10.1093/lambio/ovae051
BibTeX
@article{Monteiro2024,
author = {Monteiro, Marcos P and Kohl, Hannah M and Roullet, Jean-Baptiste and Gibson, K Michael and Ochoa-Repáraz, Javier and Castillo, Andrea R},
title = {Genetically engineered Lactococcus lactis strain constitutively expresses GABA-producing genes and produces high levels of GABA},
journal = {Letters in Applied Microbiology},
year = {2024},
doi = {10.1093/lambio/ovae051}
}
EUVIMED